<DOC>
	<DOCNO>NCT01441206</DOCNO>
	<brief_summary>The purpose study learn safety dose rifampin infant .</brief_summary>
	<brief_title>Safety Pharmacokinetics Single Multiple Dose Rifampin Infants</brief_title>
	<detailed_description>Pharmacokinetics safety rifampin studied term preterm infant receive rifampin per standard care .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Cohort 1 : Suspected systemic infection Infant &lt; 121 day age time 1st dose rifampin administration Sufficient intravascular access ( either peripheral central ) receive rifampin . Cohort 2 : Receiving rifampin per local standard care . Infant &lt; 121 day age time 1st dose rifampin administration Cohort 1 : History allergic reaction rifampin Aspartate aminotransferase ( AST ) great 3 time upper limit normal Alanine aminotransferase ( ALT ) great 3 time upper limit normal Serum creatinine great 1.7 mg.dL Urine output &lt; 0.5 mL/hr/kg prior 24 hour Any condition would make subject , opinion investigator , unsuitable study Cohort 2 :</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>121 Days</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>rifampin</keyword>
	<keyword>infant</keyword>
</DOC>